Clearmind Medicine Completes Initiation of Leading Israeli Clinical Site for Phase I/IIa Trial of CMND-100 in Alcohol Use Disorder
Clearmind Medicine (Nasdaq: CMND) has successfully completed site initiation at Tel Aviv Sourasky Medical Center (TASMC) for its Phase I/IIa clinical trial of CMND-100, a novel oral drug candidate for Alcohol Use Disorder (AUD). The trial is being conducted across multiple prestigious institutions, including Yale School of Medicine, Johns Hopkins University, and Israeli medical centers.
The study aims to evaluate the safety, tolerability, and pharmacokinetic profile of CMND-100, while also assessing early efficacy signals in reducing alcohol cravings and consumption. The drug candidate utilizes 5-methoxy-2-aminoindane (MEAI) to potentially treat AUD, which currently affects millions globally and causes 2.6 million deaths annually.
Clearmind Medicine (Nasdaq: CMND) ha completato con successo l'avvio del sito presso il Tel Aviv Sourasky Medical Center (TASMC) per il suo trial clinico di Fase I/IIa su CMND-100, un nuovo candidato farmaco orale per il Disturbo da Uso di Alcol (AUD). Lo studio viene condotto in diversi istituti prestigiosi, tra cui la Yale School of Medicine, la Johns Hopkins University e centri medici israeliani.
L'obiettivo dello studio 猫 valutare la sicurezza, la tollerabilit脿 e il profilo farmacocinetico di CMND-100, oltre a rilevare i primi segnali di efficacia nella riduzione del desiderio e del consumo di alcol. Il candidato farmaco utilizza 5-metossi-2-aminoindano (MEAI) come potenziale trattamento per l'AUD, che attualmente colpisce milioni di persone nel mondo e provoca 2,6 milioni di decessi ogni anno.
Clearmind Medicine (Nasdaq: CMND) ha completado con 茅xito la iniciaci贸n del sitio en el Tel Aviv Sourasky Medical Center (TASMC) para su ensayo cl铆nico de Fase I/IIa de CMND-100, un nuevo candidato oral para el Trastorno por Consumo de Alcohol (AUD). El estudio se est谩 llevando a cabo en varias instituciones prestigiosas, incluyendo la Escuela de Medicina de Yale, la Universidad Johns Hopkins y centros m茅dicos israel铆es.
El estudio tiene como objetivo evaluar la seguridad, tolerabilidad y perfil farmacocin茅tico de CMND-100, adem谩s de valorar se帽ales tempranas de eficacia para reducir los antojos y el consumo de alcohol. El candidato utiliza 5-metoxi-2-aminoindano (MEAI) para tratar potencialmente el AUD, que actualmente afecta a millones en todo el mundo y causa 2,6 millones de muertes anuales.
Clearmind Medicine (雮橃姢雼�: CMND)臧� 韰旍晞牍勲笇 靾橂澕鞀ろ偆 鞚橂靹柬劙(TASMC)鞐愳劀 CMND-100鞐� 雽�頃� 1/2a靸� 鞛勳儊鞁滍棙 靷澊韸� 臧滌嫓毳� 靹标车鞝侅溂搿� 鞕勲頄堨姷雼堧嫟. 鞚� 瓴疥惮鞖� 鞁犾暯 頉勲炒氍检鞚� 鞎岇綌鞓� 靷毄 鞛レ暊(AUD)毳� 雽�靸侅溂搿� 頃橂┌, 鞓堨澕 鞚橁臣雽�頃�, 臁挫姢 頇夗偍鞀� 雽�頃欔祼 霌� 鞐煬 氇呾劚 鞛堧姅 旮瓣磤瓿� 鞚挫姢霛检棙 鞚橂旮瓣磤鞐愳劀 歆勴枆霅橁碃 鞛堨姷雼堧嫟.
鞚措矆 鞐瓣惮電� CMND-100鞚� 鞎堨爠靹�, 雮挫暯靹�, 鞎诫彊頃欖爜 韸轨劚鞚� 韽夑皜頃橂姅 霃欖嫓鞐� 鞚岇＜ 鞖曣惮 氚� 靹法 臧愳唽鞐� 雽�頃� 齑堦赴 須姤 鞁犿樃霃� 頇曥澑頃橂姅 瓴冹潉 氇╉憸搿� 頃╇媹雼�. 鞚� 鞎诫 頉勲炒電� 5-氅旐哑鞁�-2-鞎勲云胳澑雼�(惭贰础滨)鞚� 頇滌毄頃橃棳 鞝� 靹戈硠 靾橂氨毵� 氇呾棎瓴� 鞓來枼鞚� 氙胳箻瓿� 鞐瓣皠 260毵� 氇呾潣 靷鞚� 齑堧灅頃橂姅 AUD毳� 旃橂頃� 臧�電レ劚鞚� 韮愱惮頃╇媹雼�.
Clearmind Medicine (Nasdaq : CMND) a achev茅 avec succ猫s l'initiation du site au Tel Aviv Sourasky Medical Center (TASMC) pour son essai clinique de phase I/IIa de CMND-100, un nouveau candidat m茅dicament oral pour le trouble li茅 脿 l'usage d'alcool (AUD). L'essai est men茅 dans plusieurs institutions prestigieuses, dont la Yale School of Medicine, l'Universit茅 Johns Hopkins et des centres m茅dicaux isra茅liens.
Cette 茅tude vise 脿 茅valuer la s茅curit茅, la tol茅rabilit茅 et le profil pharmacocin茅tique de CMND-100, tout en examinant les premiers signes d'efficacit茅 dans la r茅duction des envies et de la consommation d'alcool. Le candidat m茅dicament utilise le 5-m茅thoxy-2-aminoindane (MEAI) pour traiter potentiellement l'AUD, qui touche actuellement des millions de personnes dans le monde et cause 2,6 millions de d茅c猫s par an.
Clearmind Medicine (Nasdaq: CMND) hat die Standortfreigabe am Tel Aviv Sourasky Medical Center (TASMC) f眉r seine Phase I/IIa klinische Studie mit CMND-100, einem neuartigen oralen Arzneimittelkandidaten zur Behandlung der Alkoholkonsumst枚rung (AUD), erfolgreich abgeschlossen. Die Studie wird an mehreren renommierten Institutionen durchgef眉hrt, darunter die Yale School of Medicine, Johns Hopkins University und israelische medizinische Zentren.
Ziel der Studie ist es, die Sicherheit, Vertr盲glichkeit und das pharmakokinetische Profil von CMND-100 zu bewerten und gleichzeitig erste Wirksamkeitssignale zur Verringerung von Alkoholverlangen und -konsum zu erfassen. Der Wirkstoffkandidat nutzt 5-Methoxy-2-Aminoindan (MEAI) zur potenziellen Behandlung von AUD, das weltweit Millionen Menschen betrifft und j盲hrlich 2,6 Millionen Todesf盲lle verursacht.
- Expansion of clinical trial to prestigious medical centers including Yale, Johns Hopkins, and TASMC
- Promising preclinical results showing potential reduction in alcohol cravings
- Addressing a significant global market with 2.6 million annual deaths from AUD
- Development of non-hallucinogenic treatment option for AUD
- Early-stage clinical trial with no efficacy data yet available
- Complex multinational trial coordination across multiple centers may impact timeline
Insights
Clearmind's AUD drug CMND-100 expands Phase I/IIa trial to Tel Aviv Sourasky Medical Center, strengthening its multi-center approach investigating a novel non-hallucinogenic MEAI treatment.
Clearmind Medicine has successfully expanded its Phase I/IIa clinical trial for CMND-100 by completing site initiation at Tel Aviv Sourasky Medical Center (TASMC). This site joins an impressive roster of research institutions including Yale, Johns Hopkins, and Hadassah Medical Center, creating a robust multinational clinical network for their Alcohol Use Disorder (AUD) treatment candidate.
The trial has dual objectives: primarily evaluating safety, tolerability, and pharmacokinetics of CMND-100, while simultaneously collecting preliminary efficacy data on alcohol craving reduction and consumption patterns. This hybrid Phase I/IIa design is strategically efficient, potentially accelerating the development timeline by capturing both safety and early efficacy signals in a single study.
CMND-100's active ingredient, 5-methoxy-2-aminoindane (MEAI), represents an interesting mechanistic approach. Unlike traditional AUD medications that typically work through aversion therapy (disulfiram), opioid antagonism (naltrexone), or GABA modulation (acamprosate), MEAI appears to target alcohol cravings directly. Notably, the company emphasizes its non-hallucinogenic properties, differentiating it from classic psychedelics while still leveraging novel CNS pathways.
The clinical significance is substantial considering AUD's global impact, which causes 2.6 million deaths annually. With few effective pharmacotherapies available and high treatment discontinuation rates, the medical need remains critically underserved. Adding TASMC expands patient recruitment capacity, potentially accelerating study completion and advancing the program toward pivotal trials if early results prove promising.
Vancouver, Canada, July 23, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (鈥淐learmind鈥� or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the successful completion of site initiation at Tel Aviv Sourasky Medical Center (TASMC) for its Phase I/IIa clinical trial evaluating CMND-100, a proprietary oral drug candidate for Alcohol Use Disorder (AUD). This milestone advances Clearmind鈥檚 mission to transform treatment for the global epidemic of AUD, which affects millions and accounts for .
The Phase I/IIa trial, already underway at prestigious sites, including Yale School of Medicine and Johns Hopkins University in the United States and TASMC and Hadassah-University Medical Center in Israel, is a multinational, multi-center study assessing the safety, tolerability, and pharmacokinetic profile of CMND-100. It also explores early efficacy signals, such as reduced alcohol cravings and consumption, in patients with AUD. The inclusion of TASMC as a clinical site, where the trial is led by Prof. David Zeltser, Director of the Emergency Medicine Department at TASMC, strengthens Clearmind鈥檚 clinical network and accelerates patient enrollment in this groundbreaking trial.
鈥淲e are thrilled to complete the initiation of Tel Aviv Sourasky Medical Center, a world-class institution, in our Phase I/IIa trial for CMND-100,鈥� said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine. 鈥淭his milestone brings us closer to potentially delivering an innovative, non-hallucinogenic treatment for AUD, addressing a critical unmet need for millions worldwide. We believe that our collaboration with leading centers like TASMC, Hadassah, Yale, and Johns Hopkins underscores the scientific community鈥檚 confidence in our approach.鈥�
CMND-100, Clearmind鈥檚 lead compound, leverages the innovative molecule 5-methoxy-2-aminoindane (MEAI) to offer a potential breakthrough in AUD treatment. Preclinical studies have shown promising results in reducing alcohol cravings, positioning CMND-100 as a potentially novel therapeutic in a market with significant demand.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company鈥檚 intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol 鈥淐WY0.鈥�
For further information visit: or contact:
Investor Relations
Telephone: (604) 260-1566
US:
General Inquiries
Forward-Looking Statements:
This press release contains 鈥渇orward-looking statements鈥� within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as 鈥渆xpects,鈥� 鈥渁nticipates,鈥� 鈥渋ntends,鈥� 鈥減lans,鈥� 鈥渂elieves,鈥� 鈥渟eeks,鈥� 鈥渆stimates鈥� and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the Company鈥檚 mission to transform treatment for the global epidemic of AUD, which affects millions and accounts for 2.6 million deaths annually, potentially delivering an innovative, non-hallucinogenic treatment for AUD, addressing a critical unmet need for millions worldwide, the scientific community鈥檚 confidence in the Company鈥檚 approach, how preclinical studies have shown promising results in reducing alcohol cravings and CMND-100鈥檚 position as a potential novel therapeutic in a market with significant demand. Forward-looking statements are not historical facts, and are based upon management鈥檚 current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management鈥檚 expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company鈥檚 reports filed from time to time with the Securities and Exchange Commission (鈥淪EC鈥�), including, but not limited to, the risks detailed in the Company鈥檚 annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ
What is the purpose of Clearmind Medicine's CMND-100 Phase I/IIa clinical trial?
Which medical centers are participating in Clearmind Medicine's Phase I/IIa trial?
What is CMND-100 and how does it work?
What is the market potential for Clearmind Medicine's AUD treatment?
Who is leading the clinical trial at Tel Aviv Sourasky Medical Center?
